From brokering numerous peace deals across the globe to eliminating DEI from the federal government, President Donald Trump has already notched massive wins mere months into his second term in the Oval Office.
Adding to Trump’s growing list of achievements is his undeniable success in attracting trillions of dollars in new investment into American manufacturing, innovation, and production, a tally recently touted by the White House.
The Trump administration’s list of wins within the tech sector was highlighted in detail as part of a broader press release examining the influx of investment commitments secured to date.
Apple’s $600 billion infusion into manufacturing and workforce training was outlined, as was its pledge to bring “additional components of its supply chain and advanced manufacturing back to the U.S.”
Japan-based Softbank, together with American-based OpenAI and Oracle agreed to inject $500 billion in U.S.-based artificial intelligence infrastructure, marking yet another administration-supported success.
Global chipmaker NVIDIA joined the surge, announcing its own $500 billion spend on U.S.-based AI-infrastructure spread over the next four years, adding to its promise to build AI supercomputers completely within the United States for the first time.
IBM and Taiwan Semiconductor Manufacturing Company are also getting in on the action, with the firms poised to inject $150 billion and $100 billion into the U.S., respectively, in the years to come.
With Trump having lamented the country’s reliance on foreign manufacturers for pharmaceutical manufacturing, there has been a noted push for U.S.-centered investment on the part of drug makers, including their research and development arms.
Johnson & Johnson has stepped up, as the White House explained, vowing a spend of $55 billion over four years in “manufacturing, research and development, and technology.”
AstraZeneca and Roche each pledged $50 billion investments each for stateside research and development as well as manufacturing, with the latter’s injection of funds projected to create thousands of new jobs.
Bristol Myers Squibb and Eli Lilly joined the domestic investment push, adding their commitments of $40 billion and $27 billion, respectively, for research, development, and manufacturing.
In addition to the aforementioned tech and pharmaceutical sectors, the Trump administration has succeeded in securing sizable investment pledges from manufacturing giants such as John Deere, Stellantis, Ford, General Motors, and more.
Though critics of the president will surely attempt to diminish these accomplishments by suggesting that their likely impact is exaggerated or is accompanied by too many caveats and contingencies, others believe that Trump’s influence in this -- and many other areas -- is undeniable.
As Rich Lowry of National Review -- a longtime Trump skeptic -- recently declared, “If you had to sum up President Donald Trump’s second term so far in one word, you could do worse than ‘epic,’, adding, “Trump may be on the path to the most consequential presidency since Ronald Reagans,” a sentiment with which millions – including a host of business leaders – clearly agree.
